Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.

ABSTRACT:

SUBMITTER: Corominas J 

PROVIDER: S-EPMC10102678 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature